| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.005 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.42 | 0.006 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.092 | 0.006 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.085 | 0.007 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.007 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.008 |